Redeye comments on OncoZenge’s engagement of LINK Medical to conduct a feasibility study ahead of its European phase III trial for BupiZenge. We view this as a strategically important step in the company's clinical execution plan, aimed at optimizing trial site selection and recruitment timelines in key European markets.
LÄS MER
